Krystexxa Approved for Use with Methotrexate
July 8, 2022
Diacomit Approved for Broader Age Group
July 14, 2022
July 13, 2022 – The FDA has granted emergency use authorization to Novavax’s COVID-19 vaccine for the prevention of COVID-19 caused by the SARS-CoV-2 virus in adults.
- According to the FDA, the vaccine’s known and potential benefits outweigh its known and potential risks in people who are at least 18 years old. The new EUA expands the vaccination options available to people in the United States.
- The vaccine is administered as a two-dose primary series, with three weeks between doses.